Streetbeat News

Analyst Ratings

TSX:REAL

BMO Capital analyst Thanos Moschopoulos maintains a 'Market Perform' rating on Real Matters (TSX:REAL) and raises the price target from C$5 to C$6.

Portfolio Pulse from richadhand@benzinga.com

July 31, 2023 | 12:19 pm

ENPH

Goldman Sachs analyst Brian Lee has maintained a 'Buy' rating on Enphase Energy (NASDAQ:ENPH) but lowered the price target from $250 to $217.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 12:19 pm

LIN

BMO Capital analyst John McNulty has maintained an 'Outperform' rating on Linde (NYSE:LIN) and raised the price target from $400 to $418.

Portfolio Pulse from richadhand@benzinga.com

July 31, 2023 | 12:18 pm

BEN

BMO Capital analyst James Fotheringham maintains a Market Perform rating on Franklin Resources (NYSE:BEN) and raises the price target from $24 to $27.

Portfolio Pulse from richadhand@benzinga.com

July 31, 2023 | 12:17 pm

CHTR

Goldman Sachs analyst Brett Feldman maintains a Buy rating on Charter Communications (NASDAQ:CHTR) and raises the price target from $450 to $510.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 12:17 pm

ARCB

Goldman Sachs analyst Jordan Alliger maintains a Neutral rating on ArcBest (NASDAQ:ARCB) and raises the price target from $105 to $117.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 12:16 pm

MCHI

Jim Cramer, host of CNBC's Mad Money, expressed skepticism about China's ability to stimulate its economy while maintaining a 'guns and butter' strategy, referring to lavish spending on both defense and social programs. This comes as China's economy struggles to gain momentum following COVID-19 lockdowns, with consumer prices remaining unchanged and producer prices falling. The iShares MSCI China ETF (NASDAQ:MCHI) saw a slight increase in premarket trading.

Portfolio Pulse from Shanthi Rexaline

July 31, 2023 | 12:15 pm

ALSN

Goldman Sachs analyst Jerry Revich maintains a Sell rating on Allison Transmission (NYSE:ALSN) and raises the price target from $42 to $48.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 12:14 pm

AAPL

ADBE

BAX

CMCSA

F

GTLS

HAS

IONS

PAG

PG

TCOM

Several companies have had their price targets adjusted by various analysts. Keybanc cut Baxter International's price target from $53 to $51, while Raymond James raised Chart Industries' price target from $175 to $190. JP Morgan boosted Trip.com's price target from $39 to $50 and Citigroup increased Ionis Pharmaceuticals' price target from $36 to $60. Jefferies cut Ford Motor's price target from $17 to $15, while B of A Securities raised Hasbro's price target from $68 to $85. JP Morgan cut Penske Automotive's price target from $150 to $140, while Piper Sandler raised Apple's price target from $180 to $220. Deutsche Bank boosted Procter & Gamble's price target from $170 to $173, Barclays increased Comcast's price target from $42 to $47, and Morgan Stanley boosted Adobe's price target from $510 to $660.

Portfolio Pulse from Lisa Levin

July 31, 2023 | 12:06 pm

TSHA

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received a recommendation from the Independent Data Monitoring Committee (IDMC) to continue the REVEAL Phase 1/2 trial for Rett syndrome. The decision was based on encouraging initial clinical data from the first patient dosed with TSHA-102. The dosing of the second patient is expected in Q3 2023. TSHA-102 is an investigational gene therapy for Rett syndrome, a rare genetic neurodevelopmental disorder.

Portfolio Pulse from Happy Mohamed

July 31, 2023 | 12:05 pm